Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | GLA | P06280 | 3/20 | 1.00 |
| ▸ | ATM | Q13315 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 4/20 | 0.92 |
| ▸ | CA2 | P00918 | 4/20 | 0.92 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.82 |
| ▸ | CA12 | O43570 | 1/20 | 0.81 |
| ▸ | CA9 | Q16790 | 1/20 | 0.81 |
| ▸ | MMP2 | P08253 | 1/20 | 0.80 |
| ▸ | MMP9 | P14780 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | CFTR | P13569 | 1/20 | 0.79 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15197341 | 0.96 | CA1 (1.00) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL18827569 | 0.94 | PTGS2 (0.92) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL18826382 | 0.91 | L3MBTL1 (0.84) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL5564567 | 0.89 | L3MBTL1 (1.00) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL14484122 | 0.89 | CA1 (1.00) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL15301136 | 0.89 | KDM4E (0.88) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL18826383 | 0.89 | PTGS2 (0.85) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL15197342 | 0.88 | L3MBTL1 (0.78) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL18826375 | 0.88 | CA1 (0.91) | L3MBTL1KDM4EALDH1A1MAPTGAA | |
| SCHEMBL18826390 | 0.87 | CA12 (0.80) | L3MBTL1KDM4EALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | claimed |
| US-12433871-B2 | Effects of age-dependent changes in cell size on endothelial cell growth | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2025-10-07 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-120193076-A | Application of tumor metastasis marker and protein inhibitor and diagnostic reagent | 宁波康柏睿格医药科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| WO-2025033911-A1 | METHOD FOR REPROGRAMMING TYPE 1 ALVEOLAR CELLS INTO TYPE 2 ALVEOLAR CELLS USING RHOSIN, DASATINIB, OR ML141, AND COMPOSITION FOR INHIBITING LUNG CANCER METASTASIS CONTAINING ML141 OR DASATINIB | 가톨릭대학교 산학협력단 | 2025-02-13 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-117982491-A | Application of CDC42 protein as acting target in preparation of medicine for treating radioactive liver fibrosis | 南方医科大学南方医院 | 2024-05-07 | — | — | CN | claimed |
| WO-2023196235-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230310471-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| WO-2023091964-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF TUMOR METASTASIS AND HORIZONTAL GENE TRANSFER | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2023-05-25 | — | — | WO | claimed |
| US-20220175730-A1 | Effects of Age-Dependent Changes in Cell Size on Endothelial Cell Growth | THE MEDICAL COLLEGE OF WISCONSIN, INC. | 2022-06-09 | — | — | US | claimed |
| WO-2026106552-A1 | THERAPEUTIC CONVERSION OF CANCER CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-05-21 | — | — | WO | disclosed |
| EP-4713688-A2 | HUMAN EIF3L BINDING MOLECULES AND CANCER EXOSOME DIAGNOSTICS AND ANTI-THROMBOTIC TREATMENT | The Cleveland Clinic Foundation (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20130345277-A1 | Modulators of GTPase and Use In Relevant Treatment | Kansas University Center for Technology Commercialization, Inc. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130217744-A1 | EFFICACY IN TREATING BACTERIAL INFECTIONS | BALL STATE UNIVERSITY | 2013-08-22 | — | — | US | disclosed |
| US-20130217744-A1 | EFFICACY IN TREATING BACTERIAL INFECTIONS | BALL STATE UNIVERSITY | 2013-08-22 | — | — | US | disclosed |
| US-20130217744-A1 | EFFICACY IN TREATING BACTERIAL INFECTIONS | BALL STATE UNIVERSITY | 2013-08-22 | — | — | US | disclosed |
| WO-2012125884-A1 | DERIVATIVES OF CELECOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345277-A1 | Modulators of GTPase and Use In Relevant Treatment | KRAS, CDC42, RHOT2 | L3MBTL1 2389/4885KDM4E 4544/4885ALDH1A1 4580/4885 |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | CDC42, BMP4, TPMT | L3MBTL1 100/4885KDM4E 2577/4885ALDH1A1 4657/4885 |
| US-20220175730-A1 | Effects of Age-Dependent Changes in Cell Size on Endothelial Cell Growth | VEGFA, HGF, HDGF | L3MBTL1 1647/4885KDM4E 3645/4885ALDH1A1 4016/4885 |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | MTCL3, DYNLL2, CEP170 | L3MBTL1 1468/4885KDM4E 3839/4885ALDH1A1 4545/4885 |
| US-12433871-B2 | Effects of age-dependent changes in cell size on endothelial cell growth | VEGFA, HGF, HDGF | L3MBTL1 1647/4885KDM4E 3645/4885ALDH1A1 4016/4885 |
| US-20130217744-A1 | EFFICACY IN TREATING BACTERIAL INFECTIONS | CDC42, RAC1, CDC42BPG | L3MBTL1 1907/4885KDM4E 4262/4885ALDH1A1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.